NASDAQ:NBIX

Neurocrine Biosciences Stock Forecast, Price & News

$95.72
-0.62 (-0.64 %)
(As of 09/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$93.61
$96.40
50-Day Range
$86.18
$99.03
52-Week Range
$84.77
$120.27
Volume590,384 shs
Average Volume896,198 shs
Market Capitalization$9.05 billion
P/E Ratio25.73
Dividend YieldN/A
Beta0.73
30 days | 90 days | 365 days | Advanced Chart
Receive NBIX News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Neurocrine Biosciences logo

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm's product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.46 out of 5 stars

Medical Sector

130th out of 1,352 stocks

Biological Products, Except Diagnostic Industry

18th out of 193 stocks

Analyst Opinion: 2.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

Is Neurocrine Biosciences a buy right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Neurocrine Biosciences stock.
View analyst ratings for Neurocrine Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Neurocrine Biosciences?

Wall Street analysts have given Neurocrine Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Neurocrine Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Neurocrine Biosciences?

Neurocrine Biosciences saw a drop in short interest in the month of August. As of August 13th, there was short interest totaling 3,570,000 shares, a drop of 13.6% from the July 29th total of 4,130,000 shares. Based on an average daily volume of 738,600 shares, the days-to-cover ratio is currently 4.8 days. Currently, 3.9% of the shares of the company are short sold.
View Neurocrine Biosciences' Short Interest
.

When is Neurocrine Biosciences' next earnings date?

Neurocrine Biosciences is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Neurocrine Biosciences
.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its quarterly earnings data on Monday, August, 2nd. The company reported $0.43 earnings per share for the quarter, missing analysts' consensus estimates of $0.52 by $0.09. The firm had revenue of $288.90 million for the quarter, compared to the consensus estimate of $274.47 million. Neurocrine Biosciences had a net margin of 35.34% and a trailing twelve-month return on equity of 33.04%.
View Neurocrine Biosciences' earnings history
.

How has Neurocrine Biosciences' stock price been impacted by COVID-19?

Neurocrine Biosciences' stock was trading at $85.90 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NBIX stock has increased by 11.4% and is now trading at $95.72.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for NBIX?

15 brokers have issued 1-year price objectives for Neurocrine Biosciences' stock. Their forecasts range from $90.00 to $163.00. On average, they expect Neurocrine Biosciences' stock price to reach $119.31 in the next twelve months. This suggests a possible upside of 24.6% from the stock's current price.
View analysts' price targets for Neurocrine Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the following people:
  • Kevin Charles Gorman, Chief Executive Officer & Director
  • Bill Wilson, Vice President-Information Technology & Operations
  • Matthew C. Abernethy, Chief Financial Officer
  • Dimitri E. Grigoriadis, Chief Research Officer
  • Eiry W. Roberts, Chief Medical Officer

What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?

11 employees have rated Neurocrine Biosciences CEO Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among Neurocrine Biosciences' employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Neurocrine Biosciences' key competitors?

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), The Walt Disney (DIS), Tesla (TSLA), Square (SQ) and salesforce.com (CRM).

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.50%), Price T Rowe Associates Inc. MD (5.32%), Jefferies Group LLC (0.00%), Bellevue Group AG (3.19%), Bank of New York Mellon Corp (2.13%) and DSM Capital Partners LLC (1.62%). Company insiders that own Neurocrine Biosciences stock include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy and Stephen A Sherwin.
View institutional ownership trends for Neurocrine Biosciences
.

Which major investors are selling Neurocrine Biosciences stock?

NBIX stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Capital International Investors, Bank of New York Mellon Corp, Bellevue Group AG, Renaissance Technologies LLC, Bank of America Corp DE, Bank of America Corp DE, and Perceptive Advisors LLC. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Eiry Roberts, Eric Benevich, Gary A Lyons, Julie Cooke, Kevin Charles Gorman, Malcolm Lloyd-Smith, and Matt Abernethy.
View insider buying and selling activity for Neurocrine Biosciences
or view top insider-selling stocks.

Which major investors are buying Neurocrine Biosciences stock?

NBIX stock was bought by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Woodline Partners LP, DSM Capital Partners LLC, Vanguard Group Inc., Amundi, Allianz Asset Management GmbH, Westfield Capital Management Co. LP, and State of Wisconsin Investment Board.
View insider buying and selling activity for Neurocrine Biosciences
or or view top insider-buying stocks.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $95.72.

How much money does Neurocrine Biosciences make?

Neurocrine Biosciences has a market capitalization of $9.05 billion and generates $1.05 billion in revenue each year. The company earns $407.30 million in net income (profit) each year or $4.16 on an earnings per share basis.

How many employees does Neurocrine Biosciences have?

Neurocrine Biosciences employs 845 workers across the globe.

What is Neurocrine Biosciences' official website?

The official website for Neurocrine Biosciences is www.neurocrine.com.

Where are Neurocrine Biosciences' headquarters?

Neurocrine Biosciences is headquartered at 12780 EL CAMINO REAL, SAN DIEGO CA, 92130.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at (858) 617-7600 or via email at [email protected]


This page was last updated on 9/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.